<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32910255</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN><JournalIssue CitedMedium="Internet"><Volume>268</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>A systematic review of neuropsychiatric and cognitive assessments used in clinical trials for amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>4510</StartPage><EndPage>4521</EndPage><MedlinePgn>4510-4521</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-020-10203-z</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Up to 50% of people with amyotrophic lateral sclerosis (ALS) experience cognitive dysfunction, whilst depression and anxiety are reported in up to 44% and 33%, respectively. These symptoms impact on quality of life, and are associated with a&#xa0;poorer prognosis. Historically, outcomes in clinical trials have focused on the effect of candidate drugs on physical functioning.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We reviewed the past 25&#xa0;years of clinical trials of investigative medicinal products in people with ALS, since the licensing of riluzole, and extracted data on frequency and type of assessment for neuropsychiatric symptoms and cognitive impairment. Trial registry databases, including WHO International Trials Registry, European Clinical Trials Register, clinicaltrials.gov, and PubMed, were systematically searched for Phase II, III or IV trials registered, completed or published between 01/01/1994 and 31/10/2019. No language restrictions were applied. Outcome measures, exclusion criteria and assessment tool used were extracted.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">216 trials, investigating 26,326 people with ALS, were reviewed. 35% assessed neuropsychiatric symptoms, and 22% assessed cognition, as Exclusion Criteria or Outcome Measures. 3% (n&#x2009;=&#x2009;6) of trials assessed neuropsychiatric symptoms as a Secondary Outcome Measure, and 4% (n&#x2009;=&#x2009;8) assessed cognition as Outcome Measures; only one trial included assessments for both cognition and neuropsychiatric symptoms as Outcome Measures. Three ALS-specific assessments were used in six trials.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Trials for people with ALS have neglected the importance of neuropsychiatric symptoms and cognitive impairment. Evaluation of these extra-motor features is essential to understanding the impact of candidate drugs on all symptoms of ALS.</AbstractText><AbstractText Label="PROPSERO REGISTRATION" NlmCategory="UNASSIGNED">CRD42020175612.</AbstractText><CopyrightInformation>&#xa9; 2020. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Beswick</LastName><ForeName>Emily</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-9843-0778</Identifier><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, Scotland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, 49 Little France Crescent, EH16 4SB, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for MND Research, The University of Edinburgh, Edinburgh, Scotland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>The School of Medicine and Veterinary Medicine, The University of Edinburgh, Edinburgh, Scotland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Charis</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, Scotland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, 49 Little France Crescent, EH16 4SB, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for MND Research, The University of Edinburgh, Edinburgh, Scotland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Arpan R</ForeName><Initials>AR</Initials><Identifier Source="ORCID">0000-0002-5715-5025</Identifier><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, Scotland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, 49 Little France Crescent, EH16 4SB, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for MND Research, The University of Edinburgh, Edinburgh, Scotland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute, The University of Edinburgh, Edinburgh, Scotland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dakin</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, Scotland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, 49 Little France Crescent, EH16 4SB, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chandran</LastName><ForeName>Siddharthan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, Scotland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, 49 Little France Crescent, EH16 4SB, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for MND Research, The University of Edinburgh, Edinburgh, Scotland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute, The University of Edinburgh, Edinburgh, Scotland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newton</LastName><ForeName>Judith</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, Scotland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, 49 Little France Crescent, EH16 4SB, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carson</LastName><ForeName>Alan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, Scotland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abrahams</LastName><ForeName>Sharon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Euan MacDonald Centre for MND Research, The University of Edinburgh, Edinburgh, Scotland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Human Cognitive Neurosciences, Psychology, School of Philosophy, Psychology and Language Sciences, The University of Edinburgh, Edinburgh, Scotland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pal</LastName><ForeName>Suvankar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, Scotland. Suvankar.Pal@ed.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, 49 Little France Crescent, EH16 4SB, Edinburgh, UK. Suvankar.Pal@ed.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for MND Research, The University of Edinburgh, Edinburgh, Scotland. Suvankar.Pal@ed.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MEHTA/JUL17/948-795</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L023784/2</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/R001162/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>7LJ087RS6F</RegistryNumber><NameOfSubstance UI="D019782">Riluzole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="Y">Motor Neuron Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019782" MajorTopicYN="N">Riluzole</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Clinical trials</Keyword><Keyword MajorTopicYN="N">Cognition</Keyword><Keyword MajorTopicYN="N">Motor neuron disease</Keyword><Keyword MajorTopicYN="N">Neuropsychiatric</Keyword></KeywordList><CoiStatement>Professor Carson is a paid editor at Journal of Neurology, Neurosurgery and Psychiatry, and gives independent testimony in Court on a range of neuropsychiatric topics.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>6</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>10</Day><Hour>12</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32910255</ArticleId><ArticleId IdType="pmc">PMC8563523</ArticleId><ArticleId IdType="doi">10.1007/s00415-020-10203-z</ArticleId><ArticleId IdType="pii">10.1007/s00415-020-10203-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chio A, et al. Prognostic factors in ALS: a critical review. Amyotrophic Lateral Sclerosis. 2009;10(5&#x2013;6):310&#x2013;323. doi: 10.3109/17482960802566824.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960802566824</ArticleId><ArticleId IdType="pmc">PMC3515205</ArticleId><ArticleId IdType="pubmed">19922118</ArticleId></ArticleIdList></Reference><Reference><Citation>Wicks P, et al. Prevalence of depression in a 12-month consecutive sample of patients with ALS. Eur J Neurol. 2007;14(9):993&#x2013;1001. doi: 10.1111/j.1468-1331.2007.01843.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2007.01843.x</ArticleId><ArticleId IdType="pubmed">17718691</ArticleId></ArticleIdList></Reference><Reference><Citation>Zucchi E, Ticozzi N, Mandrioli J. Psychiatric symptoms in amyotrophic lateral sclerosis: beyond a motor neuron disorder. Front Neurosci. 2019;13:19&#x2013;67. doi: 10.3389/fnins.2019.00175.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00175</ArticleId><ArticleId IdType="pmc">PMC6421303</ArticleId><ArticleId IdType="pubmed">30914912</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston M, et al. Mood as a predictor of disability and survival in patients newly diagnosed with ALS/MND. Br J Health Psychol. 1999;4(2):127&#x2013;136. doi: 10.1348/135910799168524.</Citation><ArticleIdList><ArticleId IdType="doi">10.1348/135910799168524</ArticleId></ArticleIdList></Reference><Reference><Citation>McHutchison CA, et al. Relationship between neuropsychiatric disorders and cognitive and behavioural change in MND. J Neurol Neurosurg Psyc. 2020;91(3):245&#x2013;253. doi: 10.1136/jnnp-2019-321737.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-321737</ArticleId><ArticleId IdType="pubmed">31871139</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittchen H-U, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(9):655&#x2013;679. doi: 10.1016/j.euroneuro.2011.07.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.euroneuro.2011.07.018</ArticleId><ArticleId IdType="pubmed">21896369</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohayon MM, et al. The prevalence of depressive disorders in the United Kingdom. Biol Psychiat. 1999;45(3):300&#x2013;307. doi: 10.1016/S0006-3223(98)00011-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-3223(98)00011-0</ArticleId><ArticleId IdType="pubmed">10023506</ArticleId></ArticleIdList></Reference><Reference><Citation>Gon&#xe7;alves DC, Pachana NA, Byrne GJ. Prevalence and correlates of generalized anxiety disorder among older adults in the Australian National Survey of Mental Health and Well-Being. J Affect Disord. 2011;132(1&#x2013;2):223&#x2013;230. doi: 10.1016/j.jad.2011.02.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2011.02.023</ArticleId><ArticleId IdType="pubmed">21429587</ArticleId></ArticleIdList></Reference><Reference><Citation>Benbrika S, et al. Cognitive, emotional and psychological manifestations in amyotrophic lateral sclerosis at baseline and overtime: a review. Frontiers Neurosci. 2019;13:951. doi: 10.3389/fnins.2019.00951.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00951</ArticleId><ArticleId IdType="pmc">PMC6746914</ArticleId><ArticleId IdType="pubmed">31551700</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein LH, Abrahams S. Changes in cognition and behaviour in amyotrophic lateral sclerosis: nature of impairment and implications for assessment. Lancet Neurol. 2013;12(4):368&#x2013;380. doi: 10.1016/S1474-4422(13)70026-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70026-7</ArticleId><ArticleId IdType="pubmed">23518330</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, et al. Amyotrophic lateral sclerosis-frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria. Amyot Lateral Scle Front Degen. 2017;18(3&#x2013;4):153&#x2013;174. doi: 10.1080/21678421.2016.1267768.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1267768</ArticleId><ArticleId IdType="pmc">PMC7409990</ArticleId><ArticleId IdType="pubmed">28054827</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrahams S, et al. Verbal fluency and executive dysfunction in amyotrophic lateral sclerosis (ALS) Neuropsychologia. 2000;38(6):734&#x2013;747. doi: 10.1016/S0028-3932(99)00146-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0028-3932(99)00146-3</ArticleId><ArticleId IdType="pubmed">10689049</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor LJ, et al. Is language impairment more common than executive dysfunction in amyotrophic lateral sclerosis? J Neurol Neurosurg Psychiatry. 2013;84(5):494&#x2013;498. doi: 10.1136/jnnp-2012-303526.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-303526</ArticleId><ArticleId IdType="pubmed">23033353</ArticleId></ArticleIdList></Reference><Reference><Citation>Girardi A, MacPherson SE, Abrahams S. Deficits in emotional and social cognition in amyotrophic lateral sclerosis. Neuropsychology. 2011;25(1):53. doi: 10.1037/a0020357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/a0020357</ArticleId><ArticleId IdType="pubmed">20919762</ArticleId></ArticleIdList></Reference><Reference><Citation>Radakovic R, et al. Multidimensional apathy in ALS: validation of the Dimensional Apathy Scale. J Neurol Neurosurg Psychiatry. 2016;87(6):663&#x2013;669. doi: 10.1136/jnnp-2015-310772.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-310772</ArticleId><ArticleId IdType="pubmed">26203157</ArticleId></ArticleIdList></Reference><Reference><Citation>Katon W, Lin EH, Kroenke K. The association of depression and anxiety with medical symptom burden in patients with chronic medical illness. Gen Hosp Psychiatry. 2007;29(2):147&#x2013;155. doi: 10.1016/j.genhosppsych.2006.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.genhosppsych.2006.11.005</ArticleId><ArticleId IdType="pubmed">17336664</ArticleId></ArticleIdList></Reference><Reference><Citation>Lou J-S, et al. Fatigue and depression are associated with poor quality of life in ALS. Neurology. 2003;60(1):122&#x2013;123. doi: 10.1212/01.WNL.0000042781.22278.0A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000042781.22278.0A</ArticleId><ArticleId IdType="pubmed">12525733</ArticleId></ArticleIdList></Reference><Reference><Citation>Caga J, et al. Apathy and its impact on patient outcome in amyotrophic lateral sclerosis. J Neurol. 2018;265(1):187&#x2013;193. doi: 10.1007/s00415-017-8688-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-017-8688-4</ArticleId><ArticleId IdType="pubmed">29189922</ArticleId></ArticleIdList></Reference><Reference><Citation>Watermeyer TJ, et al. Impact of disease, cognitive and behavioural factors on caregiver outcome in amyotrophic lateral sclerosis. Amyot Lateral Scler Frontotemp Degen. 2015;16(5&#x2013;6):316&#x2013;323. doi: 10.3109/21678421.2015.1051990.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1051990</ArticleId><ArticleId IdType="pubmed">26199108</ArticleId></ArticleIdList></Reference><Reference><Citation>Bock M, et al. Cognitive-behavioral changes in amyotrophic lateral sclerosis: screening prevalence and impact on patients and caregivers. Amyot Lateral Scler Frontotemp Degen. 2016;17(5&#x2013;6):366&#x2013;373. doi: 10.3109/21678421.2016.1165257.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2016.1165257</ArticleId><ArticleId IdType="pubmed">27043386</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein L, et al. Predictors of psychological distress in carers of people with amyotrophic lateral sclerosis: a longitudinal study. Psychol Med. 2006;36(6):865&#x2013;875. doi: 10.1017/S0033291706007124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0033291706007124</ArticleId><ArticleId IdType="pubmed">16490122</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG. JD Mitchell, DH Moore, Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) Cochrane Database Syst Rev. 2012;3:6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7055506</ArticleId><ArticleId IdType="pubmed">22419278</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G, et al. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med. 1994;330(9):585&#x2013;591. doi: 10.1056/NEJM199403033300901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199403033300901</ArticleId><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Group II RS Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet. 1996;347(913):1425&#x2013;1431.</Citation><ArticleIdList><ArticleId IdType="pubmed">8676624</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanagisawa N, et al. Efficacy and safety of riluzole in patients with amyotrophic lateral sclerosis: double-blind placebo-controlled study in Japan. Igakuno Ayumi. 1997;182:851&#x2013;866.</Citation></Reference><Reference><Citation>Bhandari R, Kuhad A. Edaravone: a new hope for deadly amyotrophic lateral sclerosis. Drugs Today. 2018;54(6):349&#x2013;360. doi: 10.1358/dot.2018.54.6.2828189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1358/dot.2018.54.6.2828189</ArticleId><ArticleId IdType="pubmed">29998226</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregory JM, et al. Neuronal clusterin expression is associated with cognitive protection in amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol. 2019;3:8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7318312</ArticleId><ArticleId IdType="pubmed">31386770</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregory JM, et al. Executive, language and fluency dysfunction are markers of localised TDP-43 cerebral pathology in non-demented ALS. J Neurol Neurosurg Psychiatry. 2020;91(2):149&#x2013;157. doi: 10.1136/jnnp-2019-320807.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-320807</ArticleId><ArticleId IdType="pmc">PMC6996101</ArticleId><ArticleId IdType="pubmed">31515300</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillinger T, et al. Altered glutamatergic response and functional connectivity in treatment resistant schizophrenia: the effect of riluzole and therapeutic implications. Psychopharmacology. 2019;236(7):1985&#x2013;1997. doi: 10.1007/s00213-019-5188-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00213-019-5188-5</ArticleId><ArticleId IdType="pmc">PMC6642056</ArticleId><ArticleId IdType="pubmed">30820633</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Den Berg LH, et al. Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. Neurology. 2019;92(14):e1610&#x2013;e1623. doi: 10.1212/WNL.0000000000007242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007242</ArticleId><ArticleId IdType="pmc">PMC6448453</ArticleId><ArticleId IdType="pubmed">30850440</ArticleId></ArticleIdList></Reference><Reference><Citation>National CGCU. Motor Neurone Disease. Assess Managt. 2016;4:9.</Citation></Reference><Reference><Citation>De Carvalho M, et al. A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. Amyot Lateral Scler Frontotemp Degen. 2010;11(5):456&#x2013;460. doi: 10.3109/17482968.2010.498521.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2010.498521</ArticleId><ArticleId IdType="pubmed">20565333</ArticleId></ArticleIdList></Reference><Reference><Citation>Group, U.-L.S. Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial. The Lancet Neurol. 2013;12(4):339&#x2013;345. doi: 10.1016/S1474-4422(13)70037-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70037-1</ArticleId><ArticleId IdType="pmc">PMC3610091</ArticleId><ArticleId IdType="pubmed">23453347</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller R, et al. Phase II/III randomized trial of TCH346 in patients with ALS. Neurology. 2007;69(8):776&#x2013;784. doi: 10.1212/01.wnl.0000269676.07319.09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000269676.07319.09</ArticleId><ArticleId IdType="pubmed">17709710</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold J, et al. Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial. Amyot Lateral Scler Frontotemp Degen. 2019;20(7&#x2013;8):595&#x2013;604. doi: 10.1080/21678421.2019.1632899.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1632899</ArticleId><ArticleId IdType="pubmed">31284774</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammer EM, et al. Validity of the ALS-Depression-Inventory (ADI-12)&#x2014;a new screening instrument for depressive disorders in patients with amyotrophic lateral sclerosis. J Affect Disord. 2008;109(1&#x2013;2):213&#x2013;219. doi: 10.1016/j.jad.2007.11.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2007.11.012</ArticleId><ArticleId IdType="pubmed">18262283</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck AT, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4(6):561&#x2013;571. doi: 10.1001/archpsyc.1961.01710120031004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archpsyc.1961.01710120031004</ArticleId><ArticleId IdType="pubmed">13688369</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharp R. The Hamilton rating scale for depression. Occup Med. 2015;65(4):340&#x2013;340. doi: 10.1093/occmed/kqv043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/occmed/kqv043</ArticleId><ArticleId IdType="pubmed">25972613</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson ME, et al. Columbia&#x2013;suicide severity rating scale scoring and data analysis guide. CSSRS Scoring. 2013;2:1&#x2013;13.</Citation></Reference><Reference><Citation>Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361&#x2013;370. doi: 10.1111/j.1600-0447.1983.tb09716.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0447.1983.tb09716.x</ArticleId><ArticleId IdType="pubmed">6880820</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308&#x2013;2308. doi: 10.1212/WNL.44.12.2308.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.44.12.2308</ArticleId><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y-P, Gorenstein C. Assessment of depression in medical patients: a systematic review of the utility of the Beck Depression Inventory-II. Clinics. 2013;68(9):1274&#x2013;1287. doi: 10.6061/clinics/2013(09)15.</Citation><ArticleIdList><ArticleId IdType="doi">10.6061/clinics/2013(09)15</ArticleId><ArticleId IdType="pmc">PMC3782729</ArticleId><ArticleId IdType="pubmed">24141845</ArticleId></ArticleIdList></Reference><Reference><Citation>Mottram P, Wilson K, Copeland J. Validation of the Hamilton Depression Rating Scale and Montgommery and Asberg Rating Scales in terms of AGECAT depression cases. Internat J Geriat Psych. 2000;15(12):1113&#x2013;1119. doi: 10.1002/1099-1166(200012)15:12&lt;1113::AID-GPS253&gt;3.0.CO;2-Y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1099-1166(200012)15:12&lt;1113::AID-GPS253&gt;3.0.CO;2-Y</ArticleId><ArticleId IdType="pubmed">11180467</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbons CJ, et al. Rasch analysis of the hospital anxiety and depression scale (HADS) for use in motor neurone disease. Health Quality life Outcomes. 2011;9(1):82. doi: 10.1186/1477-7525-9-82.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1477-7525-9-82</ArticleId><ArticleId IdType="pmc">PMC3192662</ArticleId><ArticleId IdType="pubmed">21955749</ArticleId></ArticleIdList></Reference><Reference><Citation>Posner K, et al. The Columbia-Suicide severity rating scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266&#x2013;1277. doi: 10.1176/appi.ajp.2011.10111704.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.2011.10111704</ArticleId><ArticleId IdType="pmc">PMC3893686</ArticleId><ArticleId IdType="pubmed">22193671</ArticleId></ArticleIdList></Reference><Reference><Citation>Giddens JM, Sheehan KH, Sheehan DV. The Columbia-Suicide Severity Rating Scale (C&#x2013;SSRS): Has the &#x201c;gold standard&#x201d; become a liability? Innov Clin Neurosci. 2014;11(9&#x2013;10):66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4267801</ArticleId><ArticleId IdType="pubmed">25520890</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufer DI, et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsyc Clin Neurosci. 2000;12(2):233&#x2013;239. doi: 10.1176/jnp.12.2.233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/jnp.12.2.233</ArticleId><ArticleId IdType="pubmed">11001602</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai CK. The merits and problems of Neuropsychiatric Inventory as an assessment tool in people with dementia and other neurological disorders. Clin Interv Aging. 2014;9:1051. doi: 10.2147/CIA.S63504.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CIA.S63504</ArticleId><ArticleId IdType="pmc">PMC4099101</ArticleId><ArticleId IdType="pubmed">25031530</ArticleId></ArticleIdList></Reference><Reference><Citation>Woolley SC, et al. Detecting frontotemporal dysfunction in ALS: utility of the ALS Cognitive Behavioral Screen (ALS-CBS&#x2122;) Amyot Lateral Scler. 2010;11(3):303&#x2013;311. doi: 10.3109/17482961003727954.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482961003727954</ArticleId><ArticleId IdType="pubmed">20433413</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrahams S, et al. Screening for cognition and behaviour changes in ALS. Amyot Lateral Scler Frontotemp Degen. 2014;15(1&#x2013;2):9&#x2013;14. doi: 10.3109/21678421.2013.805784.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.805784</ArticleId><ArticleId IdType="pubmed">23781974</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasreddine ZS, et al. The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695&#x2013;699. doi: 10.1111/j.1532-5415.2005.53221.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.2005.53221.x</ArticleId><ArticleId IdType="pubmed">15817019</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathuranath P, et al. A brief cognitive test battery to differentiate Alzheimer's disease and frontotemporal dementia. Neurology. 2000;55(11):1613&#x2013;1620. doi: 10.1212/01.wnl.0000434309.85312.19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000434309.85312.19</ArticleId><ArticleId IdType="pubmed">11113213</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy J, Ahmed F, Lomen-Hoerth C. The UCSF screening exam effectively screens cognitive and behavioral impairment in patients with ALS. Amyot Lateral ScleR Frontotemp Degen. 2015;16(1&#x2013;2):24&#x2013;30. doi: 10.3109/21678421.2014.960873.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.960873</ArticleId><ArticleId IdType="pubmed">25301548</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. The measurement and appraisal of adult intelligence MD. USA: Williams and Wilkins; 1958.</Citation></Reference><Reference><Citation>Glasmacher S. The prevalence of multimorbidity and its impact on prognosis in motor neuron disease. Edinburgh: The University of Edinburgh; 2020.</Citation></Reference><Reference><Citation>Mioshi E, Roberts R, Hornberger M. Neuropsychiatric symptoms and survival in amyotrophic lateral sclerosis: a missing link? Neurodegen Dis Manag. 2015;5(2):89&#x2013;91. doi: 10.2217/nmt.15.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/nmt.15.1</ArticleId><ArticleId IdType="pubmed">25894870</ArticleId></ArticleIdList></Reference><Reference><Citation>Phukan J, Pender NP, Hardiman O. Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol. 2007;6(11):994&#x2013;1003. doi: 10.1016/S1474-4422(07)70265-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(07)70265-X</ArticleId><ArticleId IdType="pubmed">17945153</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodgins F, Mulhern S, Abrahams S. The clinical impact of the Edinburgh Cognitive and Behavioural ALS Screen (ECAS) and neuropsychological intervention in routine ALS care. Amyot Lateral Scler Frontotemp Degen. 2019;1:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">31612737</ArticleId></ArticleIdList></Reference><Reference><Citation>Niven E, et al. Validation of the Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen (ECAS): a cognitive tool for motor disorders. Amyot Lateral Scler Frontotemp Degen. 2015;16(3&#x2013;4):172&#x2013;179. doi: 10.3109/21678421.2015.1030430.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1030430</ArticleId><ArticleId IdType="pubmed">25967542</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H, et al. ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): study methodology, recruitment, and baseline demographic and disease characteristics. Amyot Lateral Scler Frontotemp Degen. 2014;15(3&#x2013;4):192&#x2013;203. doi: 10.3109/21678421.2013.864312.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.864312</ArticleId><ArticleId IdType="pmc">PMC4310702</ArticleId><ArticleId IdType="pubmed">24564738</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy J, et al. Cognitive-behavioral screening reveals prevalent impairment in a large multicenter ALS cohort. Neurology. 2016;86(9):813&#x2013;820. doi: 10.1212/WNL.0000000000002305.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002305</ArticleId><ArticleId IdType="pmc">PMC4793785</ArticleId><ArticleId IdType="pubmed">26802094</ArticleId></ArticleIdList></Reference><Reference><Citation>Woolley S, et al. Longitudinal screening detects cognitive stability and behavioral deterioration in ALS patients. Behav Neurol. 2018;2:18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6234441</ArticleId><ArticleId IdType="pubmed">30515252</ArticleId></ArticleIdList></Reference><Reference><Citation>Crockford C, et al. ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS. Neurology. 2018;91(15):e1370&#x2013;e1380. doi: 10.1212/WNL.0000000000006317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006317</ArticleId><ArticleId IdType="pmc">PMC6177274</ArticleId><ArticleId IdType="pubmed">30209236</ArticleId></ArticleIdList></Reference><Reference><Citation>Elamin M, et al. Cognitive changes predict functional decline in ALS: a population-based longitudinal study. Neurology. 2013;80(17):1590&#x2013;1597. doi: 10.1212/WNL.0b013e31828f18ac.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31828f18ac</ArticleId><ArticleId IdType="pubmed">23553481</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrahams S, Leigh P, Goldstein L. Cognitive change in ALS: a prospective study. Neurology. 2005;64(7):1222&#x2013;1226. doi: 10.1212/01.WNL.0000156519.41681.27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000156519.41681.27</ArticleId><ArticleId IdType="pubmed">15824350</ArticleId></ArticleIdList></Reference><Reference><Citation>Atassi N, et al. Depression in amyotrophic lateral sclerosis. Amyot Lateral Scler. 2011;12(2):109&#x2013;112. doi: 10.3109/17482968.2010.536839.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2010.536839</ArticleId><ArticleId IdType="pmc">PMC3155886</ArticleId><ArticleId IdType="pubmed">21091399</ArticleId></ArticleIdList></Reference><Reference><Citation>Mioshi E, et al. The Addenbrooke's Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening. Internat J Geriat Psych Life Allied Sci. 2006;21(11):1078&#x2013;1085. doi: 10.1002/gps.1610.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gps.1610</ArticleId><ArticleId IdType="pubmed">16977673</ArticleId></ArticleIdList></Reference><Reference><Citation>Osborne RA, et al. Screening for frontal lobe and general cognitive impairment in patients with amyotrophic lateral sclerosis. J Neurol Sci. 2014;336(1&#x2013;2):191&#x2013;196. doi: 10.1016/j.jns.2013.10.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2013.10.038</ArticleId><ArticleId IdType="pubmed">24239183</ArticleId></ArticleIdList></Reference><Reference><Citation>Kertesz A, et al. The Frontal Behavioral Inventory in the differential diagnosis of frontotemporal dementia. J Internat Neuropsychol Soc. 2000;6(4):460&#x2013;468. doi: 10.1017/S1355617700644041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1355617700644041</ArticleId><ArticleId IdType="pubmed">10902415</ArticleId></ArticleIdList></Reference><Reference><Citation>Dick J, et al. Mini-mental state examination in neurological patients. J Neurol Neurosurg Psychiatry. 1984;47(5):496&#x2013;499. doi: 10.1136/jnnp.47.5.496.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.47.5.496</ArticleId><ArticleId IdType="pmc">PMC1027826</ArticleId><ArticleId IdType="pubmed">6736981</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, The PRISMA Group Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009;6(7):e1000097. doi: 10.1371/journal.pmed1000097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed1000097</ArticleId><ArticleId IdType="pmc">PMC2707599</ArticleId><ArticleId IdType="pubmed">19621072</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>